Eli Lilly's Retatrutide Shows Promising Results in Weight Loss and Related Health Improvements
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
Image: Benzinga
Eli Lilly's investigational drug, retatrutide, demonstrated significant efficacy in reducing weight, A1C levels, knee osteoarthritis pain, and obstructive sleep apnea severity in recent Phase 3 trials, highlighting its potential as a comprehensive treatment for obesity and its complications.
- 01In the TRIUMPH-1 trial, participants lost an average of 70.3 lbs (28.3%) over 80 weeks with retatrutide 12 mg.
- 0265.3% of participants achieved a BMI below 30, indicating a significant reduction in obesity.
- 03In TRANSCEND-T2D-1, retatrutide led to A1C reductions of up to 2.0%, with 90% of participants achieving an A1C below 7.0%.
- 04Retatrutide also improved knee osteoarthritis pain by up to 73.1% and obstructive sleep apnea severity by 60.6%.
- 05The trials included over 2,300 participants and demonstrated significant cardiovascular risk factor improvements.
Advertisement
In-Article Ad
Eli Lilly and Company's investigational drug, retatrutide, has shown remarkable potential in treating obesity and its related complications, according to results from pivotal Phase 3 trials TRIUMPH-1 and TRANSCEND-T2D-1. In TRIUMPH-1, participants receiving retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30. The drug also significantly alleviated knee osteoarthritis pain by up to 73.1% and reduced obstructive sleep apnea severity by 60.6%. In the TRANSCEND-T2D-1 trial, retatrutide led to A1C reductions of up to 2.0%, with 90% of participants reaching an A1C below 7.0%. The trials involved over 2,300 participants and highlighted the drug's ability to address multiple obesity-related health issues simultaneously, potentially transforming treatment approaches for obesity and its complications. Adverse events were generally mild to moderate, consistent with other therapies in this class.
Advertisement
In-Article Ad
The findings from the trials suggest that retatrutide could significantly improve health outcomes for individuals suffering from obesity and its related complications, potentially reducing healthcare costs associated with managing these conditions.
Advertisement
In-Article Ad
Reader Poll
What do you think about the potential of retatrutide for treating obesity?
Connecting to poll...
More about Eli Lilly and Company
Eli Lilly réduit ses investissements en Allemagne en raison de réformes de santé
Investing French • Jun 3, 2026
Kelonia Therapeutics Reports Promising Phase 1 Results for KLN-1010 CAR-T Therapy at ASCO 2026
Businesswire • May 31, 2026
Eli Lilly dévoile des résultats prometteurs sur Foundayo et retatrutide à l'ADA
Investing French • May 28, 2026
Read the original article
Visit the source for the complete story.